The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The potential of MDM2 inhibitors in the treatment of MPN
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, discusses the potential of murine double minute 2 (MDM2) inhibitors in treating myeloproliferative neoplasms (MPN). These agents show promise for patients who have failed other treatments. Further research is needed to determine their long-term efficacy and whether they are most effective as monotherapy or in combination. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Novartis, BMS, GSK; Speaker Bureau: Novartis, GSK, Incyte; Clinical Trial Support: BMS.
